Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Southern Cancer Center Clear all
Active, not recruiting No phase listed Observational

Molecular Studies and Clinical Correlations in Human Prostatic Disease

NCT00578240
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
5,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Not listed No phase listed Observational

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers

NCT01936376
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 24, 2026, 5:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Childhood Cancer Survivor Study

NCT01120353
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

NCT01522768
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Afatinib and Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 24, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk

NCT01649661
View directory record Official record
Conditions
Cancer Free Women
Interventions
questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
437 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 24, 2026, 5:01 AM EDT
Active, not recruiting Phase 2 Interventional

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

NCT01873326
View directory record Official record
Conditions
Germ Cell Tumors
Interventions
Paclitaxel, Ifosfamide, Cisplatin, Mesna, Bleomycin, Etoposide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Completed No phase listed Observational

A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer

NCT02888366
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Montclair, New Jersey • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 24, 2026, 5:01 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

NCT02642913
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Enzalutamide, Enzalutamide with Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
San Francisco, California • St Louis, Missouri • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 24, 2026, 5:01 AM EDT
Terminated No phase listed Observational

Clinical Performance Evaluation of the C2i-Test

NCT05221827
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
C2i Test
Diagnostic Test
Lead sponsor
C2i Genomics
Industry
Eligibility
22 Years to 100 Years
Enrollment
3 participants
Timeline
2022
U.S. locations
1
States / cities
Bloomfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 24, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Onset and Familial Gastric Cancer Registry

NCT00582257
View directory record Official record
Conditions
Gastric Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 24, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial

NCT02535845
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Project Voice, HPV Informational Video
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

NCT00910650
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 24, 2026, 5:01 AM EDT
Terminated Not applicable Interventional

A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors

NCT03172832
View directory record Official record
Conditions
Cholangiocarcinoma, Hilar Lymphadenopathy, Biliary Stricture
Interventions
PTBD, ERC
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Los Angeles, California • New Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 24, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nutrition for Precision Health, Powered by the All of Us

NCT05701657
View directory record Official record
Conditions
Nutrition, Health, Dietary Habits
Interventions
Diet A, Diet B, Diet C
Other
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development of Psychotherapeutic Interventions for Parents Who Lost a Child

NCT02153619
View directory record Official record
Conditions
Parents Who Have Lost a Child
Interventions
Meaning-Centered Grief Therapy (MCGT), Supportive Psychotherapy (SP), questionnaires assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Recruiting No phase listed Observational

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

NCT00588068
View directory record Official record
Conditions
Neuroblastoma
Interventions
Tumor and Marrow Markers
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
2,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

NCT01229150
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
AZD6244, Erlotinib, AZD6244 + Erlotinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Davis, California • Los Angeles, California • South Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 24, 2026, 5:01 AM EDT
Completed No phase listed Observational

Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer

NCT00579462
View directory record Official record
Conditions
Lung Cancer
Interventions
Blood and Tissue studies
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

NCT01404949
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
Tretinoin and Arsenic Trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

NCT00908960
View directory record Official record
Conditions
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Interventions
Enoxaparin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 24, 2026, 5:01 AM EDT
Not listed No phase listed Observational

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

NCT01543620
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 24, 2026, 5:01 AM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 24, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

NCT04160065
View directory record Official record
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 24, 2026, 5:01 AM EDT